Congenital Middle Ear Malformation with Common Deafness Gene Mutation Analysis: A Review of 813 Profound Sensorineural Hearing Loss Child Patients

Deafness gene variants play a key role in inner ear malformations. However, the relationship between congenital middle ear malformations and common deafness genes (GJB2, SLC26A4, and mtDNA) in profound sensorineural hearing loss (SNHL) child patients remains poorly investigated. Here we showed that there was no statistical significance in the total mutation frequency of the three common deafness genes in the middle ear malformation group (21.2%, 41/193) in comparison with the normal middle ear and inner ear group (21.0%, 116/553) (χ² = 0.0061, p = 0.940). Moreover, the mutation ratio of GJB2 and SLC26A4 in the middle ear malformation group (18.7%, 36/193; 2.6%, 5/193) was not significantly different from that in the normal middle ear and inner ear group (17.7%, 98/553; 2.4%, 13/553) (χ² = 0.084, p = 0.772; χ² = 0.0000, p = 1.000). The mutation ratio of GJB2 235delC and GJB2 79G>A in the middle ear malformation group (8.8%, 17/193; 8.8%, 17/193) was almost the same to that in the normal middle ear and inner ear group (8.6%, 48/553; 6.7%, 37/553) (χ² = 0.0030, p = 0.957; χ² = 0.9556, p = 0.328). The high jugular bulb subgroup analysis also showed the same results. Our findings suggested that GJB2, SLC26A4, and mtDNA mutations might not be related to the middle ear malformations in profound SNHL child patients. Anat Rec, 303:594–599, 2020. © 2019 American Association for Anatomy     

听源性惊厥大鼠脑星形胶质细胞Xx43表达增加对神经元保护的机制

Epilepsyisoneofthecommonandfrequentdiseases,anditharmshumanhealthseriously.Theratwithaudiogenicseizureistheanimalmodelofchronicexperimentalepilepsydeterminedbyheredity.Theseizureiscontrolledandsimilarwithsomeprimaryepilepsyofhuman,soithasbeenregardedasidealanimalmodeltodiscussprimaryepilepsyofhumanandanti-epilepsydrug犤1犦.Withdevelopmentofresearchaboutpathogenicmechanismofepilepsyandfurthercognitionofastrocytefunctionundernormalandpathologicalconditions,astrocytehasbeenthoughtthatitplayarolei…     

糖尿病并发冠心病患者血中TXB_2、6—Keto—PGF_(1α)和LPO的含量变化及其临床意义

应用放射免疫法和硫代巴比妥酸荧光法测定了52例糖尿病并发冠心病患者血中TXB_26—keto—PGF_(1α)和LPO的含量,并与37例非糖尿病性冠心病患者作了对比分析。结果发现:糖尿病并发冠心病患者血中TXB_2、LPO含量和TXB_2/6—Keto—PGF_(1α)比值明显增高,6—Keto—PGF_(12)含量无明显变化。提示糖尿病并发冠心病患者体内TXA_2/PGF_(1α)比例失衡和氧自由基的氧化损伤反应较无糖尿病的冠心病患者严重。这可能是糖尿病患者冠心病发病率高、起病早、发展快、病情重、预后差的重要原因之一。     

Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester

Globally, COVID-19 vaccines are currently being used to prevent transmission and to reduce morbidity and death associated with SARS-CoV-2 infection. Current research reveals that vaccines such as BNT162b2 and Ad26.COV2.S are highly immunogenic and have high short-term effectiveness for most of the known viral variants. Clinical trials showed satisfying results in the general population, but the reluctance in testing and vaccinating pregnant women left this category with little evidence regarding the safety, efficacy, and immunogenicity following COVID-19 vaccination. With the worldwide incidence of COVID-19 remaining high and the possibility of new transmissible SARS-CoV-2 mutations, data on vaccination effectiveness and antibody dynamics in pregnant patients are critical for determining the need for special care or further booster doses. An observational study was developed to evaluate pregnant women receiving the complete COVID-19 vaccination scheme using the BNT162b2 and Ad26.COV2.S, and determine pregnancy-related outcomes in the mothers and their newborns, as well as determining adverse events after vaccination and immunogenicity of vaccines during four months. There were no abnormal findings in pregnancy and newborn characteristics comparing vaccinated versus unvaccinated pregnant women. COVID-19 seropositive pregnant women had significantly higher spike antibody titers than seronegative patients with similar characteristics, although they were more likely to develop fever and lymphadenopathy following vaccination. The same group of pregnant women showed no statistically significant differences in antibody titers during a 4-month period when compared with case-matched non-pregnant women. The BNT162b2 and Ad26.COV2.S vaccines are safe to administer during the third trimester of pregnancy, while their safety, efficacy, and immunogenicity remain similar to those of the general population.